FGF23 and cardiac hypertrophy: In this context, augmented fibroblast growth factor-23 (FGF23) signalling as well as Klotho deficiency have been implicated as novel mediators of heart hypertrophy in the general population and in patients with chronic kidney disease (CKD)4–6.